A new study finds four factors that may make it more likely for some people to experience successful weight loss from using ...

Women and older adults taking the anti-obesity drug semaglutide may be at higher risk for muscle loss, but higher protein ...

Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

Semaglutide is marketed under the brand names, such as Ozempic, which is primarily prescribed for those with Type 2 diabetes, and Wegovy, which is commonly prescribed for weight loss. The drug mimics ...

As weight loss jabs like Ozempic become ever more popular, doctors are growing increasingly concerned about their gnarly side ...

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...

A Wellington man is stoked to finally get his hands back on the weight loss drug he said changed his life. Wegovy was approved for weight loss in March 2025 with a doctor’s prescription. The drug ...

Novo Nordisk's pipeline, especially the oral GLP-1 and Alzheimer’s trial, offers significant long-term upside. Click here to ...

The exact numbers depended on the type of medication patients took, but the risk of developing Alzheimer’s was up to 70 ...

Wegovy® is indicated for chronic weight management in adults and adolescents (12+) with obesity or overweight and at least ...

Semaglutide is a drug originally developed for diabetes that was approved for weight loss in 2021. Hailed as a "game-changer," it works by curbing appetite and can make people's cravings disappear ...

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a maintenance fee in 2019.